Mild Cognitive Impairment Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Biogen Inc., Eisai Co., Eli Lilly and Company, Alzheon Inc., AriBio Co., TauRx Therapeutics

Posted on
by

Mild Cognitive Impairment Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Biogen Inc., Eisai Co., Eli Lilly and Company, Alzheon Inc., AriBio Co., TauRx Therapeutics
The Key Mild Cognitive Impairment Companies in the market include – FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others.

 

DelveInsight’s “Mild Cognitive Impairment Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mild Cognitive Impairment, historical and forecasted epidemiology as well as the Mild Cognitive Impairment market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Mild Cognitive Impairment market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mild Cognitive Impairment Market Forecast

 

Some of the key facts of the Mild Cognitive Impairment Market Report:

  • The Mild Cognitive Impairment market size was valued ~USD 2,836 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In April 2025, At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Alzheon shared findings from its Phase III APOLLOE4 (NCT04770220) trial during a company-sponsored symposium. The study evaluated ALZ-801 (valiltramiprosate), an oral small molecule that blocks the formation of neurotoxic amyloid beta (Aβ) oligomers, in patients with early-stage Alzheimer’s disease—specifically those with mild cognitive impairment (MCI) or mild Alzheimer’s—who are homozygous carriers of the APOE4 gene.

  • In December 2024, Blarcamesine (ANAVEX2-73) has been accepted for review by the EMA for the treatment of Alzheimer’s disease. This submission was supported by positive findings from the ANAVEX2-73-AD-004 clinical trial, which involved patients in the early stages of Alzheimer’s.

  • As of December 2024, TauRx is actively engaging with the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) concerning its UK Marketing Authorisation Application (MAA) for hydromethylthionine mesylate (HMTM), a 4 mg oral tablet aimed at treating mild cognitive impairment due to Alzheimer’s (MCI-AD) and mild to moderate Alzheimer’s disease.

  • In July 2024, The US FDA has granted approval to KISUNLA (donanemab-azbt, 350 mg/20 mL), an Alzheimer’s treatment developed by Eli Lilly. The therapy is intended for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment (MCI) and mild dementia confirmed to have amyloid pathology.

  • In October 2024, AgeneBio reported that its Phase 2B trial of AGB101 showed a 40% reduction in clinical decline and notable slowing of entorhinal cortex atrophy in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease who are non-carriers of the ApoE-4 allele, compared to placebo. The ongoing findings from the HOPE4MCI trial strongly support continued evaluation of AGB101 in this specific patient group. The company is currently conducting an extension of the study in the US (NCT05986721).

  • In 2023, the United States held the largest market share for Mild Cognitive Impairment among the 7MM, with an estimated value of around USD 1,467 million, and this figure is projected to grow by 2034.

  • The existing Mild Cognitive Impairment market comprises approved treatments like LEQEMBI (lecanemab) and off-label options such as cholinesterase inhibitors, memantine, and others, collectively reaching a market size of USD 222 million across the 7MM in 2023.

  • In 2023, Japan’s Mild Cognitive Impairment market was valued at approximately USD 670 million, representing around 24% of the total 7MM market, with projections indicating further growth by 2034.

  • According to DelveInsight’s analysis, the estimated number of diagnosed prevalent cases of Parkinson’s disease in the US reached approximately 1.21 million in 2023.

  • In 2023, Germany reported the highest number of diagnosed prevalent Alzheimer’s disease cases among European countries, with around 1.49 million cases. France followed with approximately 1.17 million cases, while the UK had the lowest prevalence, with about 620 thousand diagnosed individuals.

  • In Japan, around 2.73 million diagnosed cases of Mild Cognitive Impairment were recorded, with approximately 103,000 linked to Parkinson’s disease and about 2.63 million associated with Alzheimer’s. Forecasts indicate that by 2034, cases related to Alzheimer’s will rise further, continuing to outnumber those related to Parkinson’s, emphasizing the growing burden of Alzheimer’s on the aging population.

  • According to DelveInsight’s analysis, the United States had the highest number of diagnosed prevalent cases of Mild Cognitive Impairment among the 7MM, with approximately 4.22 million cases reported in 2023. However, forecasts suggest that the United Kingdom is expected to surpass others and lead in diagnosed cases by 2034.

  • Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others

  • Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others

  • The Mild Cognitive Impairment market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Cognitive Impairment pipeline products will significantly revolutionize the Mild Cognitive Impairment market dynamics.

 

Mild Cognitive Impairment Overview

Between the predicted cognitive loss associated with normal ageing and the more substantial decline associated with dementia is a period known as mild cognitive impairment (MCI). It is characterised by issues with thinking, judgement, language, and memory.

 

Get a Free sample for the Mild Cognitive Impairment Market Report:

https://www.delveinsight.com/report-store/mild-cognitive-impairment-market

 

Mild Cognitive Impairment Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Mild Cognitive Impairment Epidemiology Segmentation:

The Mild Cognitive Impairment market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Mild Cognitive Impairment

  • Prevalent Cases of Mild Cognitive Impairment by severity

  • Gender-specific Prevalence of Mild Cognitive Impairment

  • Diagnosed Cases of Episodic and Chronic Mild Cognitive Impairment

 

Download the report to understand which factors are driving Mild Cognitive Impairment epidemiology trends @ Mild Cognitive Impairment Epidemiology Forecast

 

Mild Cognitive Impairment Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mild Cognitive Impairment market or expected to get launched during the study period. The analysis covers Mild Cognitive Impairment market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mild Cognitive Impairment Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Mild Cognitive Impairment Therapies and Key Companies

  • LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.

  • KISUNLA (Donanemab): Eli Lilly and Company

  • Valiltramiprosate (ALZ-801): Alzheon Inc.

  • Mirodenafil (AR1001): AriBio Co., Ltd.

  • Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics

  • T-817MA: FUJIFILM Toyama Chemical Co. Ltd.

  • NYX-458: Aptinyx

  • Aptinyx: AgeneBio

  • T-817MA: FUJIFILM Toyama Chemical Co., Ltd.

  • Aricept (donepezil hydrochloride): Eisai Inc.

  • CX516: RespireRx

  • AL-208: Allon Therapeutics

  • CST-2032: CuraSen Therapeutics, Inc.

  • ladostigil hemitartrate: Avraham Pharma

  • AZD5213: AstraZeneca

  • SAGE-718: Sage Therapeutics

  • fesoterodine: Pfizer

  • MMH-MAP: Materia Medica Holding

  • Donanemab: Eli Lilly and Company

  • Flutemetamol (18F) Injection: GE Healthcare

  • EVP-0962: Parexel

 

Discover more about therapies set to grab major Mild Cognitive Impairment market share @ Mild Cognitive Impairment Treatment Market

 

Scope of the Mild Cognitive Impairment Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others

  • Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others

  • Mild Cognitive Impairment Therapeutic Assessment: Mild Cognitive Impairment current marketed and Mild Cognitive Impairment emerging therapies

  • Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment market drivers and Mild Cognitive Impairment market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Mild Cognitive Impairment Unmet Needs, KOL’s views, Analyst’s views, Mild Cognitive Impairment Market Access and Reimbursement

 

To know more about Mild Cognitive Impairment companies working in the treatment market, visit @ Mild Cognitive Impairment Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Mild Cognitive Impairment Market Report Introduction

2. Executive Summary for Mild Cognitive Impairment

3. SWOT analysis of Mild Cognitive Impairment

4. Mild Cognitive Impairment Patient Share (%) Overview at a Glance

5. Mild Cognitive Impairment Market Overview at a Glance

6. Mild Cognitive Impairment Disease Background and Overview

7. Mild Cognitive Impairment Epidemiology and Patient Population

8. Country-Specific Patient Population of Mild Cognitive Impairment

9. Mild Cognitive Impairment Current Treatment and Medical Practices

10. Mild Cognitive Impairment Unmet Needs

11. Mild Cognitive Impairment Emerging Therapies

12. Mild Cognitive Impairment Market Outlook

13. Country-Wise Mild Cognitive Impairment Market Analysis (2020–2034)

14. Mild Cognitive Impairment Market Access and Reimbursement of Therapies

15. Mild Cognitive Impairment Market Drivers

16. Mild Cognitive Impairment Market Barriers

17. Mild Cognitive Impairment Appendix

18. Mild Cognitive Impairment Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/